Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus;Revue de l'efficacité et de l'innocuité d'une administration hebdomadaire d'exénatide pour le traitement du diabète type 2

Annals of Pharmacotherapy

Volumn 46, Issue 6, 2012, Pages 812-821

  Murphy, Catherine E ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Bydureon; Exenatide extended release; Exenatide once weekly; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

ADD ON THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CLINICAL EFFECTIVENESS; DIET THERAPY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HUMAN; INJECTION SITE NODULE; INJECTION SITE REACTION; KIDNEY DISEASE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; STOMACH EMPTYING; SYSTEMATIC REVIEW; THYROID CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; RECEPTORS, GLUCAGON; TREATMENT OUTCOME; VENOMS;

EID: 84862253577     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q722     Document Type: Article

References (42)

1. 2011 National diabetes fact sheet. Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/pubs/factsheet11.htm (accessed 2011 Oct10).
2. Diabetes data & trends. Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/statistics/prev/national/figpersons.htm (accessed 2011 Dec 1).
3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
4. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. BMJ 2011;343: d4169. DOI 10.1136/bmj.d4169
5. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011;34:S11-61.
6. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in US adults? Diabetes Care 2008;31:81-6.
7. Orozco LJ, Buchleitner AM, Gimenez-Perez G, et al. Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev 2008:CD003054.
8. Look AHEAD Research Group. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 2007;30:1374-83.
9. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59.
10. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009;32:193-203.
11. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallelgroup, multinational, open-label trial (LEAD -6). Lancet 2009;374:39-47.
12. Product information. Bydureon (exenatide extended-release for injectable suspension). San Diego, CA: Amylin Pharmaceuticals, Inc., January 2012.
13. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin- 4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35.
14. Defronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin- 4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100.
15. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin- 4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91.
16. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-86.
17. Product information. Victoza (liraglutide). Bagsvaerd, Denmark: Novo Nordisk Inc., May 2011.
18. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40.
19. Fact Sheet Medisorb microspheres technology. January 2009. www.biotechinvest.net/uploads/Medisorb.pdf (accessed 2011 Dec 7).
20. Kim D, MacConell L, Zhuang D, et al. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 2007;30:1487-93.
21. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50.
22. Fineman M, Flanagan S, Taylor K, et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011;50:65-74.
23. Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-10.
24. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet 2010;376:431-9.
25. Russell-Jones D, Cuddihy RM, Hanefeld M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35:252-8.
26. Diamant M, Gaal LV, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43.
27. Buse JB, Nauck MA, Forst T, et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study (abstract 75). Presented at: European Association for the Study of Diabetes Annual Meeting; September 12-16, 2011; Lisbon, Portugal.
28. Buse JB, Drucker DJ, Taylor KI, et al. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61.
29. Taylor K, Gurney K, Han J, et al. Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years. BMC Endocrine Disorders 2011;11:9.
30. Wysham C, Bergenstal R, Malloy J, et al. DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabet Med 2011;28:705-14.
31. Maggs D, Walsh B, Li Y, et al. Exenatide once weekly: sustained improvement in glycaemic control and weight loss through 3 years (abstract 783). Presented at: European Association for the Study of Diabetes Annual Meeting; September 12-16, 2011; Lisbon, Portugal.
32. Diamant M, Van Gaal L, Stranks S, et al. Safety and efficacy of onceweekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012;35:683-9.
33. Sager P, Darpo B, Han J, et al. Exenatide once weekly did not affect QTc interval in patients with type 2 diabetes (abstract 802). Presented at: European Association for the Study of Diabetes Annual Meeting; September 12-16, 2011; Lisbon, Portugal.
34. Malone J, Walsh B, Pencek R, et al. Efficacy and safety of exenatide once weekly across background therapies: a pooled analysis of DURATION studies (abstract 780). Presented at: European Association for the Study of Diabetes Annual Meeting; September 12-16, 2011; Lisbon, Portugal.
35. Iyer SN, Drake AJ 3rd, West RL, et al. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract 2012;18:e10-3.
36. Information for Healthcare Professionals: Exenatide. Food and Drug dministration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm (accessed 2012 Apr 27).
37. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-71.
38. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 2009;32:84-90.
39. Gill A, Hoogwerf BJ, Burger J, et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010;9:6.
40. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22.
41. Best JH, Hoogwerf BJ, Herman WH, et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose- lowering therapies. Diabetes Care 2011;34:90-5.
42. Exenatide study of cardiovascular event lowering trial (EXSCEL): a trial to evaluate cardiovascular outcomes after treatment with exenatide once weekly in patients with type 2 diabetes mellitus. http://clinicaltrials.gov/ct2/show/NCT01144338 (accessed 2012 Apr 27).